Ocaperidone

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Ocaperidone
Ocaperidone.svg
Names
IUPAC name
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one
Identifiers
  • 129029-23-8
3D model (JSmol)
  • Interactive image
ChemSpider
  • 64451
  • 46
KEGG
  • D02675
MeSH C072259
PubChem CID
  • 71351
Properties
C24H25FN4O2
Molar mass 420.49 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Ocaperidone (also R 79598) is a benzisoxazole antipsychotic.[1] It was initially developed by Janssen, later licensed to French laboratory Neuro3D and then acquired in 2007 by German company Evotec. Its testing was abandoned after phase II trials, as of 22 February 2010.[2]

References

  1. ^ Leysen, JE; Janssen, PM; Gommeren, W; Wynants, J; Pauwels, PJ; Janssen, PA (1992). "In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone". Molecular Pharmacology. 41 (3): 494–508. PMID 1372084. 
  2. ^ "Ocaperidone — AdisInsight". Adis Insight. Adis International Ltd, part of Springer Science+Business Media. Retrieved 10 December 2015. 



Retrieved from "https://en.wikipedia.org/w/index.php?title=Ocaperidone&oldid=723293735"
This content was retrieved from Wikipedia : http://en.wikipedia.org/wiki/Ocaperidone
This page is based on the copyrighted Wikipedia article "Ocaperidone"; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA